서울대학교 중앙도서관

S-Space 소개

My S-Space

로그인이 필요합니다.

Login

S-Space

Browse

Author

Jump to a point in the index

Or type in a year

Sort by
In order
Results/Page
Authors/record

Showing results 1 to 7 of 7

Issue Date	Title / Author(s) / Citation	File	Altmetrics
2006-04	Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients Park, Y. H.; Lee, J. J.; Ryu, M. H.; Kim, S. Y.; Kim, D. H.; Do, Y. R.; Lee, K. H.; Oh, S. J.; Kim, Y. K.; Suh, C. W.; Heo, D. S.; RYoo, B. Y.; Kim, J. K.; Song, H. S.; Lee, W. S.; Kim, H. J.; Bang, Y. J.; Yang, S. H.; Sohn, S. K.; Kang, Y. K. Annals of Hematology, Vol.85 No.4, pp.257-262	DOI
2006-04	Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin Han, J. Y.; Lim, H. S.; Shin, E. S.; Yoo, Y. K.; Park, Y. H.; Lee, J. E.; Jang, I. J.; Lee, D. H.; Lee, J. S. J Clin Oncol. 2006 May 20;24(15):2237-44. Epub 2006 Apr 24.	view file link
2016-06	Dual mode gelation behavior of silk fibroin microgel embedded poly(ethylene glycol) hydrogels Ryu, S.; Kim, H. H.; Park, Y. H.; Lin, C. -C.; Um, I. C.; Ki, CHANG SEOK Journal of Materials Chemistry B, Vol.4 No.26, pp.4574-4584	DOI
2020-04	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS Park, Y. H.; Senkus-Konefka, E.; Im, S. -A.; Pentheroudakis, G.; Saji, S.; Gupta, S.; Iwata, H.; Mastura, M. Y.; Dent, R.; Lu, Y. -S.; Yin, Y.; Smruti, B. K.; Toyama, T.; Malwinder, S.; Lee, S. C.; Tseng, L. -M.; Kim, J. H.; Kim, T. -Y.; Suh, K. J.; Cardoso, F.; Yoshino, T.; Douillard, J. -Y. Annals of Oncology, Vol.31 No.4, pp.451-469	DOI
2020-05	Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study Schmid, P.; Salgado, R.; Park, Y. H.; Munoz-Couselo, E.; Kim, S. B.; Sohn, J.; Im, S. -A.; Foukakis, T.; Kuemmel, S.; Dent, R.; Yin, L.; Wang, A.; Tryfonidis, K.; Karantza, V.; Cortes, J.; Loi, S. Annals of Oncology, Vol.31 No.5, pp.569-581	DOI
2021-10	Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11) Cho, E. H.; Kim, J. -Y.; Im, S. -A.; Jung, K. H.; Sohn, J.; Lee, K. S.; Chae, Y. S.; Lee, K. H.; Kim, J. H.; Jang, J. -H.; Ahn, J. H.; Park, M. S.; Lee, S. -Y.; Park, Y. H. Esmo Open, Vol.6 No.5, p. 100236	DOI
2022-02	Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer Schmid, P.; Cortes, J.; Dent, R.; Pusztai, L.; McArthur, H.; Kummel, S.; Bergh, J.; Denkert, C.; Park, Y. H.; Hui, R.; Harbeck, N.; Takahashi, M.; Untch, M.; Fasching, P. A.; Cardoso, F.; Andersen, J.; Patt, D.; Danso, M.; Ferreira, M.; Mouret-Reynier, M-A; Im, S-A; Ahn, J-H; Gion, M.; Baron-Hay, S.; Boileau, J-F; Ding, Y.; Tryfonidis, K.; Aktan, G.; Karantza, V; O'Shaughnessy, J. New England Journal of Medicine, Vol.386 No.6, pp.556-567	DOI

1